Notes Receivable and Other Long-term Receivables (Narrative) (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended			0 Months Ended	1 Months Ended					1 Months Ended
	Mar. 31, 2012 Notes Receivable [Member] Wellstat Diagnostics [Member]	Aug. 31, 2012 Notes Receivable [Member] Wellstat Diagnostics [Member]	Jul. 31, 2012 Notes Receivable [Member] Merus Labs [Member]	Feb. 28, 2013 Credit Agreement [Member] Wellstat Diagnostics [Member]	Jan. 31, 2013 Credit Agreement [Member] Wellstat Diagnostics [Member]	Nov. 02, 2012 Credit Agreement [Member] Wellstat Diagnostics [Member]	Jul. 31, 2012 Credit Agreement [Member] Merus Labs [Member]	Mar. 31, 2013 Initial Loan [Member] Merus Labs [Member]	Mar. 31, 2013 Additional Loan [Member] Merus Labs [Member]	Oct. 31, 2012 Royalty Agreement [Member] AxoGen [Member]
Accounts Notes And Loans Receivable [Line Items]
Financing receivable, gross	$ 7,500	$ 10,000	$ 35,000			$ 40,000
Term of receivable (in Duration)	2 years
Interest rate of note receivable (in Percent)	10.00%	12.00%						13.50%	14.00%
Credit agreement, stated interest rate (in Percent)						5.00%
Proceeds received under remedies available for borrower's breach of terms credit agreement					8,100
Amount company has agreed to advance under credit agreement				7,900
Forbearance period under terms of credit agreement (in Duration)				120 days
Letter of credit extended							20,000
Remaining purchase price obligation							20,000
Term of royalty agreement (in Duration)										8 years
Total consideration paid to AxoGen for the royalty rights										20,800
Initial interim funding for royalty rights										$ 1,800